Sucampo Pharmaceuticals Increases Sales but Misses Estimates on Earnings
Sucampo Pharmaceuticals (NAS: SCMP) reported earnings on March 13. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Sucampo Pharmaceuticals whiffed on revenue and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped significantly and GAAP earnings per share increased.
Gross margin contracted, operating margin dropped, and net margin improved.
Sucampo Pharmaceuticals reported revenue of $12.4 million. The one analyst polled by S&P Capital IQ expected to see sales of $15.5 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $12.4 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at -$0.15. The one earnings estimate compiled by S&P Capital IQ averaged -$0.01 per share on the same basis. GAAP EPS were $0.06 for Q4 versus -$0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 46.1%, 4,620 basis points worse than the prior-year quarter. Operating margin was -52.7%, 4,410 basis points worse than the prior-year quarter. Net margin was 19.0%, 4,240 basis points better than the prior-year quarter.
Next year's average estimate for revenue is $55.0 million.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 62 members out of 72 rating the stock outperform, and 10 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 13 give Sucampo Pharmaceuticals a green thumbs-up, and two give it a red thumbs-down.
The drug and healthcare investing landscape is littered with also-rans and a few major winners. Is Sucampo Pharmaceuticals the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add Sucampo Pharmaceuticals to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.